BALTIMORE (AP) — Maryland’s biggest city has filed an antitrust lawsuit against a biotechnology company it accuses of inflating costs for its prostate cancer drug.

Baltimore announced Monday it has filed suit to recover damages from Jannsen Biotech, Inc, part of Johnson & Johnson. Among other things, Baltimore alleges that Janssen pursued “sham litigation” and tried inflating costs for Zytiga, a prostate cancer drug that’s earned billions of dollars.

Baltimore claims its prescription drug plans were unjustly forced into paying “inflated” prices since 2016 when the company’s original patent expired.

Michelle Larkin is a Janssen spokeswoman. She said in a Monday email that the biotech company “stands by its decision to defend the validity and infringement of the relevant patent.”

Baltimore’s law department is co-counsel with a lawyer at a Washington firm.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.